Cabozantinib has several targets

Cabotinib is a multi-target small molecule tyrosine kinase inhibitor, known as the "Taiwan Balm" among targeted drugs. Its unique pharmacological effects enable it to show broad effectiveness in the treatment of various cancers.

Caboozantinib has 9 targets. These targets are: MET, VEGFR1, VEGFR2, VEGFR3, ROS1, RET, AXL, NTRK, KIT. These targets play key roles in the occurrence, development, and metastasis of cancer. By inhibiting these targets, cabozantinib blocks tumor cell signaling, thereby inhibiting tumor growth and spread.

1.METTarget: MET is a tyrosine kinase receptor that is overexpressed in a variety of cancers and is closely related to tumor invasion and metastasis. Cabozantinib can prevent the proliferation and migration of tumor cells by inhibiting the activity of MET.

2.VEGFR targets (including VEGFR1, VEGFR2, VEGFR3): These targets are vascular endothelial growth factor receptors, which play a key role in tumor angiogenesis. By inhibiting the activity of these receptors, cabozantinib can block the formation of tumor blood vessels, thereby cutting off the nutrient supply to the tumor.

3.ROS1, RETTargets: These are tyrosine kinase receptors for proto-oncogenes that are abnormally activated in certain types of cancer. Cabozantinib can inhibit the activity of these receptors, thereby inhibiting the growth and proliferation of tumor cells.

4.AXL, NTRK, KITTarget: These are also tyrosine kinase receptors associated with cancer. By inhibiting the activity of these targets, cabozantinib can interfere with the signal transduction of tumor cells, thereby achieving anti-tumor effects.

Because cabozantinib has so many targets, it has shown broad-spectrum anti-cancer capabilities in a variety of solid tumors. Whether in thyroid cancer, kidney cancer, liver cancer or other types of cancer, cabozantinib has demonstrated significant therapeutic effects. This multi-target feature also gives cabozantinib a unique position and value in the field of anti-cancer drugs.